Early, but encouraging data from Asterias on stem cells for spinal cord injury

Asterias

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy.  However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the …

Early, but encouraging data from Asterias on stem cells for spinal cord injury Read More »